ANI Pharma (ANIP) Misses Q2 EPS by 1c

ANI Pharma (NASDAQ: ANIP) reported Q2 EPS of $0.67, $0.01 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $48.05 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Nike names former Pfizer CFO David Denton as new finance chief